Mosunetuzumab

Mosunetuzumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Lupus、Systemic Lupus Erythematosus、Lupus Nephritis、Hodgkin Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Mosunetuzumab 研究

• Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

  II 期招募中美国NCT06569680

• Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

  II 期招募中芬兰挪威NCT05849857

• A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

  I 期 / II 期招募中美国澳大利亚Brazil中国NCT06634589

• CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

  II 期招募中美国NCT05260957

• Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  III 期招募中美国NCT06337318

• Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma

  II 期招募中中国NCT07555470

• Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

  II 期招募中美国加拿大NCT05886036

• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

  I 期招募中美国澳大利亚中国法国NCT05091424

• A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  II 期招募中ArgentinaBrazilColombia意大利NCT07598396

• Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  I 期招募中美国NCT06015880

• Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

  II 期招募中美国NCT06453044

• Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

  II 期招募中美国NCT04792502

• A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

  II 期招募中美国NCT06563505

• Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

  II 期招募中美国NCT06948786

• A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

  II 期招募中美国NCT05615636

• Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

  II 期招募中美国NCT06594939

• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  II 期招募中美国NCT05633615

• Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .

  II 期招募中IsraelNCT07191249

• Mosunetuzumab for CLL MRD Clearance

  I 期 / II 期招募中美国NCT07052695

• Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

  I 期 / II 期招募中美国NCT06249191

• Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  II 期招募中美国NCT05672251

• Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

  不适用招募中意大利NCT07278921

• A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

  II 期招募中美国NCT05389293

• A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

  I 期 / II 期招募中美国Chile中国法国NCT06090539

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。